Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zomedica Pharmaceuticals (TSXV:ZOM) will delist its common shares from the TSX Venture Exchange, as of February 10th 2020.
  • This move is the result of the shares’ low trading value on the TSXV, and the high cost of maintaining a duel listing.
  • The company’s common shares will continue trading on the New York Stock Exchange American, which has represented 99% of Zomedica’s trading volume since January 2019.
  • Zomedica’s share price on the TSXV has remained unchanged, with shares trading at $0.31 apiece. Zomedica’s share price on the NYSE American has gone up 1.91 per cent, with shares trading at $0.24 apiece.

Veterinary diagnostic and pharmaceuticals company Zomedica (ZOM) has received approval to delist its common shares from the TSX Venture Exchange. This will take effect at close of business on February 10th 2020.

This move is due to low share trading value on the TSXV, and a reevaluation of the need for a dual listing.

Zomedica’s common shares will continue to be traded on the New York Stock Exchange American.

Since January 2019, trading on the NYSE American has represented roughly 99% of Zomedica’s trading volume, and is expected to continue being the primary source of capital.

The company’s Canadian shareholders will be able to continue trading shares on the NYSE American, under the code ZOM.

Zomedica’s share price on the TSXV has remained unchanged, with shares trading at $0.31 apiece. Zomedica’s share price on the NYSE American has gone up 1.91 per cent, with shares trading at $0.24 apiece.

More From The Market Herald

" Medicenna (TSX:MDNA) announces publication of MDNA11 preclinical data

Medicenna Therapeutics Corp. (MDNA) announced the publication of preclinical data on MDNA11.

" Clearmind Medicine (CSE:CMND) engages the Independent Trading Group as a market maker and Thunder11 as a PR agency

Clearmind Medicine Inc. (CMND) has engaged the services of Independent Trading Group to provide market-making services.

" Psyched Wellness (CSE:PSYC) provides update on study with the National Research Council of Canada

Psyched Wellness (PSYC) has released preliminary data from its study with the National Research Council of Canada (NRC).
codikoat, covid protection

" PharmaDrug (CSE:PHRX) begins manufacturing PD-001 for treatment of rare cancers and COVID-19

PharmaDrug (PHRX) has begun manufacturing PD-001, its oral formulation of cepharanthine, for cancer and infectious disease studies.